

Microwave-assisted synthesis of curcumin analogs

Christie E. Nichols, Dani Youssef,^a Robert G. Harris, and Amitabh Jha*

Department of Chemistry, Acadia University, Wolfville, NS, Canada

^aDépartement des Sciences, Université Sainte-Anne, Church Point, NS, Canada

E-mail : amitabh.jha@acadiau.ca

Abstract

Curcumin, a 1,7-diaryl-1,6-heptadiene-3,5-dinone, has attracted considerable attention worldwide owing to its outstanding biological properties. Microwave-assisted expeditious synthesis of numerous cyclic analogs of curcumin under solvent-free and environmentally-benign conditions in moderate to excellent yields is reported here.

Keywords: Curcumin, microwave, aldol condensation, solvent-free, diarylheptanoids

Introduction

Curcumin (**1**) is a phytochemical obtained from *Curcuma longa*, commonly known as turmeric, a spice widely used in South-East Asia. It has attracted a lot of attention due to its promising biological properties to treat cancer,¹ Alzheimer's disease,² HIV,^{3,4} chronic inflammations,² oxidative stress,⁵ and cystic fibrosis.⁶ Curcumin underwent clinical trial for cancer owing to its prominent activity as an antitumor and chemopreventive agent.⁷ However, this trial ceased due to poor bioavailability of the molecule.^{8,9} Clinical trials are ongoing to test the efficacy of curcumin against Alzheimer's disease¹⁰ and cystic fibrosis.¹¹ Intense research is also being undertaken to modify the structure of curcumin so as to increase the bioavailability and potency while maintaining the relative non-toxic nature of this natural product.^{4,12-17}





Figure 1. Tautomeric structure of curcumin (**1**).

We are interested in the development of novel curcumin analogs with improved biological profiles.¹⁶ Although curcumin is a simple symmetrical β -diketone, its synthesis is not a straightforward di-aldol condensation on 2,4-pentadione.¹⁸ The C-3 of 2,4-pentadione bears more acidic protons than those on C-1/C-5 and therefore aldol condensations on terminal methyl groups (C-1 and C-5) must be carried out successively via the dienolate; this is hard to obtain and reaction at C-3 often leads to side products.¹⁹ Use of boron-based protection of the 1,3-diketone circumvents the Knoevenagel condensation at C-3 and facilitates aldol condensations at C-1 and C-5 of 2,4-pentadione.¹⁸ A boron-based reagent such as boron oxide, boric acid and tributoxyboron complex as Lewis acids with the β -diketone systems and consequently reduces the nucleophilicity of the C-3 position and the reaction occurs at the terminal active methylenes resulting in diarylheptanoids (Scheme 1).^{17,18,20}



Scheme 1. Generic reaction for the preparation of diarylheptanoids like curcumin.


Unlike 2,4-pentadione, 2-acetylcycloalkanones not only have a more nucleophilic and more crowded active methine, but are also very prone to ring cleavage under aqueous basic conditions.²¹ A procedure reported for condensation of aromatic aldehydes on cyclic β -diketones involved the use of 1 molar equivalent of boron oxide in presence of catalytic amounts of morpholine and acetic acid under solvent-free heating conditions.²⁰ The complexation with boron oxide also protects the 2-acetylcycloalkanones from potential ring cleavage reaction.²⁰ The reported yields under these conditions are moderate to good; however, the work-up conditions pose difficulties in purification of compounds.

We herein report a modification of this procedure with significant improvement in yields, reaction time and purity of isolated products.

Results and Discussion

Numerous microwave-assisted aldol condensations have been reported²²⁻²⁴ but the use of microwave energy in carrying out boron-assisted regioselective aldol condensation was not found in literature. Owing to the simplicity, rapidity, turnover and environment friendliness, use of microwave in organic synthesis has become very popular.²²⁻²⁵ Since the reported procedure for synthesis of carbocyclic analogs of curcumin involved heating conditions, it appeared logical to attempt their synthesis under microwave irradiation conditions. Moderate to excellent yields of the desired compounds were obtained when the reaction mixture was irradiated for 1 minute by

microwaves. It should be noted that the reactions were carried out in a conventional microwave oven at highest power where the control of the reaction course is not ideal; however we found these reactions to be qualitatively (based on tlc intensities) reproducible.



Scheme 1. Synthetic scheme for making compounds **2a-h** and **3a-g**.

A modified work-up procedure made the isolation and purification of compounds simpler. As indicated in the experimental section, the yields of the compounds made under this investigation under microwave-assisted conditions are consistently higher than those reported under conventional conditions. Although the work-up conditions are generally product specific, the work-up of relatively non-polar compounds was straightforward. Digestion in methanol produced reasonably pure product in powder form. Polar products (**2d**, **2f**, **3d** and **3f**) containing a hydroxyl group had appreciable solubility in methanol and were purified by column chromatography.

The compounds were characterized by spectroscopic means and by comparison to reported data wherever possible.²⁰ NMR spectra revealed that the compounds exist in enol form in solution. The H-bonded hydroxyl proton of the enol form expected in highly deshielded region ($>\delta$ 13) was not always seen; the active methine (-COCHCO-) of the diketo tautomer was never observed. When subjected to HR-MS, all compounds concurred very well with calculated values. The biological activity of these compounds will be published subsequently.

Conclusions

In conclusion, an efficient, expeditious and simple procedure for the synthesis of carbocyclic curcumin analogues has been developed. It furnishes the desired compound with greater purity and moderate to excellent yields.

Experimental Section

General Procedures. All chemicals and reagents were obtained from Aldrich Chemical Co. Column chromatography purifications were undertaken using silica gel (230-400 mesh) obtained from Silicycle. ¹H NMR and ¹³C NMR were recorded on Bruker AV300 NMR spectrometer. EI-

MS and HR-MS spectra were obtained on CEC 21-110B Sector instrument. Melting points were recorded on an electro-thermal apparatus and are uncorrected. UV-Vis and IR spectra were recorded on LKB Biochrom Ultraspec Plus 4054 and Nicolet Avatar 330FT-IR spectrophotometers respectively. A domestic 1.2 cu. ft. microwave oven equipped with a turntable manufactured by Kenmore with 4kV DC operating voltage was used for the microwave-assisted reactions. The highest power (900 W) and operating frequency (2450 MHz) were employed.

General synthesis of carbocyclic curcumin analogs 2a-h and 3a-g. The cycloalkanone (10 mmol) was mixed with the boron oxide (10 mmol) in a 50 mL Erlenmeyer flask. The appropriate aromatic aldehyde (20 mmol), acetic acid (50 mg), and morpholine (50 mg) were then added. The reaction was irradiated with the microwave at high power for 1 minute. The flask was cooled for 2 minutes and then methanol (30 mL) was added. This mixture was then sonicated until a fine powder was obtained. The product so obtained was filtered and washed with cold methanol. Compounds **2d**, **2f**, **3d** and **3f** did not respond favourably to methanol treatment and consequently they were purified by silica gel column chromatography using dichloromethane-methanol as gradient solvent for elution.

2-[(E)-(3-Phenylacryloyl)]-5-[1-phenylmeth-(E)-ylidene]cyclopentanone (2a). Yellow solid; yield 83% (lit.²⁰ yield 75%); m.p. 163-165 °C (lit.²⁰ m.p. 165-168 °C). ¹H NMR (300 MHz, CDCl₃): δ 2.92 (2H, t, J=6.0 Hz, CH₂), 3.04-3.19 (2H, m, CH₂), 6.71 (1H, d, J=15.7 Hz, *E*-vinylic H), 7.34-7.67 (11H, m, ArH, vinylic-H) and 7.73 (1H, d, J=15.7 Hz, *E*-vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 23.45, 26.99, 114.36, 120.69, 128.44, 129.13, 129.23, 129.34, 130.40, 130.66, 131.06, 135.76, 136.46, 139.37, 140.49, 171.06 and 193.76. IR, KBr Disc, ν: 3418, 3053, 2953, 1635, 1442, 758 and 689 cm⁻¹. UV-Vis MeOH, λ_{max}: 240, 313 and 374 nm. MS (EI) 70eV, *m/z* (rel. intensity): 302 (M⁺, 100), 225 (4), 197 (3.7) and 131 (3.4). HRMS calculated for C₂₁H₁₈O₂: 302.1307, found: 302.1318.

2-[(E)-3-(4-Chlorophenyl)acryloyl]-5-[1-(4-chlorophenyl)-meth-(E)-ylidene]-cyclopentanone (2b). Yellow solid; yield 77%; m.p. 223-225 °C. ¹H NMR (300 MHz, DMSO-d₆): δ 2.91 (2H, t, J=5.4 Hz, CH₂), 3.00-3.04 (2H, m, CH₂), 6.67 (1H, d, J=15.6 Hz, *E*-vinylic H), 7.30-7.54 (9H, m, ArH, vinylic-H) and 7.62 (1H, d, J=15.6 Hz, *E*-vinylic H). ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 23.42, 26.91, 114.54, 121.10, 129.40, 129.60, 129.62, 129.76, 131.74, 134.18, 134.87, 135.16, 136.32, 139.18, 139.76, 170.96 and 193.36. IR, KBr Disc, ν: 3424, 2931, 1632, 1384, 1093, 819 and 518 cm⁻¹. UV-Vis MeOH, λ_{max}: 242 nm. MS (EI) 70eV, *m/z* (rel. intensity): 372 ([M+2], 74), 370 (M⁺, 100), 329 (63), 248 (44.5), 191 (43) and 125 (30). HRMS calculated for C₂₁H₁₆Cl₂O₂: 370.0527, found: 370.0529.

2-[(E)-3-*p*-Tolylacryloyl]-5-[1-*p*-tolylmeth-(E)-ylidene]cyclopentanone (2c). Orange needles; yield 76%; m.p. 202-204 °C. ¹H NMR (300 MHz, CDCl₃): δ 2.40 (6H, s, CH₃), 2.89 (2H, t, J=6.3 Hz, CH₂), 3.00-3.09 (2H, m, CH₂), 6.68 (1H, d, J=15.3 Hz, *E*-vinylic H), 7.21-7.26 (4H, m, ArH), 7.36 (1H, s, vinylic H), 7.46-7.50 (4H, m, ArH) and 7.63 (1H, d, J=15.3 Hz, *E*-vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 21.91, 23.43, 26.99, 114.13, 119.66, 128.43, 128.76, 129.89, 130.08, 130.69, 131.02, 133.08, 133.74, 138.45, 139.55, 140.36, 140.82, 170.95 and 193.91. IR,

KBr Disc, ν : 3423, 2915, 1629, 1578, 1384 and 808 cm^{-1} . UV-Vis MeOH, λ_{max} : 220 and 305 nm. MS (EI) 70eV, m/z (rel. intensity): 330 (M^+ , 100), 288 (13), 171 (35), 145 (75), 115 (40) and 91 (26). HRMS calculated for $\text{C}_{23}\text{H}_{22}\text{O}_2$: 330.1620, found: 330.1627.

2-[(E)-3-(4-Hydroxyphenyl)acryloyl]-5-[1-(4-hydroxyphenyl)meth-(E)-ylidene]-cyclopentanone (2d). Dark orange solid; yield 74%; m.p. >260 °C. ^1H NMR (300 MHz, DMSO- d_6): δ 2.84 (2H, t, $J=6.3$ Hz, CH_2), 2.91-2.94 (2H, m, CH_2), 6.69 (1H, d, $J=15.6$ Hz, *E*-vinylic H), 6.81 (2H, d, $J=8.4$, ArH) 6.86 (2H, d, $J=8.4$, ArH), 7.16 (1H, s, vinylic H), 7.45-7.51 (3H, m, ArH, *E*-vinylic H), 7.60 (2H, d, $J=8.1$ Hz, ArH), 10.02 (1H, brs, OH) and 10.06 (1H, brs, OH). ^{13}C NMR (75 MHz, CDCl_3): δ 23.16, 26.87, 49.46, 114.19, 116.74, 117.82, 127.09, 127.61, 130.91, 131.20, 133.13, 136.65, 140.41, 159.49, 160.56, 170.46 and 194.04. IR, KBr Disc, ν : 3431, 1630, 1598, 1496, 1384, 1247, 1168, 1075 and 973 cm^{-1} . UV-Vis MeOH, λ_{max} : 220 and 251 nm. MS (EI) 70eV, m/z (rel. intensity): 334 (M^+ , 4), 317 (9), 254 (70) and 107 (94). HRMS calculated for $\text{C}_{21}\text{H}_{18}\text{O}_4$: 334.1205, found: 334.1216. ESI-MS (-ve ion mode), m/z (rel. intensity): 333 ([$\text{M}-1$], 100).

2-[(E)-3-(4-Methoxyphenyl)acryloyl]-5-[1-(4-methoxyphenyl)-meth-(E)-ylidene]-cyclopentanone (2e). Dark yellow solid; yield 89%; m.p. 200-201 °C. ^1H NMR (300 MHz, CDCl_3): δ 2.89 (2H, t, $J=6.6$ Hz, CH_2), 2.96-3.05 (2H, m, CH_2), 3.87 (6H, s, $2 \times \text{OCH}_3$), 6.55 (1H, d, $J=15.6$ Hz, *E*-vinylic H) 6.91-6.99 (4H, m, ArH), 7.24-7.37 (2H, m, ArH) and 7.53-7.66 (4H, m, ArH, 2 x vinylic H). ^{13}C NMR (75 MHz, CDCl_3): δ 23.39, 26.91, 55.77, 55.81, 113.76, 114.64, 114.79, 118.34, 128.65, 129.38, 130.06, 130.65, 132.35, 137.12, 139.84, 160.51, 161.58, 170.72 and 193.97. IR, KBr Disc, ν : 3430, 2932, 1624, 1583, 1510, 1440, 1384, 1251, 1176, 1029 and 818 cm^{-1} . UV-Vis MeOH, λ_{max} : 220, 249 and 339 nm. MS (EI) 70eV, m/z (rel. intensity): 362 (M^+ , 100), 228 (2.34), 202 (8), 159 (2.3) and 134 (3.2). HRMS calculated for $\text{C}_{23}\text{H}_{22}\text{O}_4$: 362.1518, found: 362.1513.

2-[(E)-3-(4-Hydroxy-3-methoxyphenyl)acryloyl]-5-[1-(4-hydroxy-3-methoxyphenyl)-meth-(E)-ylidene]cyclopentanone (2f). Dark orange solid; yield 80% (lit.²⁰ yield 62%); m.p. 221-224 °C (lit.²⁰ m.p. 224-227 °C). ^1H NMR (300 MHz, DMSO- d_6): δ 2.87 (2H, t, $J=5.7$ Hz, CH_2), 2.96-2.99 (2H, m, CH_2), 3.83 (3H, s, OCH_3), 3.84 (3H, s, OCH_3), 6.73 (1H, d, $J=15.6$ Hz, *E*-vinylic H), 6.80-6.89 (3H, m, ArH), 7.10-7.19 (3H, m, ArH), 7.35 (1H, s, vinylic H), 7.49 (1H, d, $J=15.6$ Hz, vinylic H), 9.63 (1H, brs, OH) and 9.66 (1H, brs, OH). ^{13}C NMR (75 MHz, DMSO- d_6): δ 23.29, 26.79, 56.45, 56.65, 112.42, 114.24, 115.06, 116.56, 116.72, 118.04, 123.91, 125.07, 127.57, 128.10, 131.29, 136.86, 140.83, 148.53, 148.84, 149.02, 150.13, 170.50 and 194.00. IR, KBr Disc, ν : 3512, 3424, 2933, 1626, 1573, 1514, 1384, 1278, 1120, 1036 and 955 cm^{-1} . UV-Vis MeOH, λ_{max} : 220 and 265 nm. MS (EI) 70eV, m/z (rel. intensity): 394 (M^+ , 0.1), 261 (95.3), 260 (100), 245 (40) and 137 (6). HRMS calculated for $\text{C}_{23}\text{H}_{22}\text{O}_6$: 394.1416, found: 394.1410.

2-[(E)-3-(3,4-Dimethoxyphenyl)acryloyl]-5-[1-(3,4-dimethoxyphenyl)-meth-(E)-ylidene]cyclopentanone (2g). Reddish brown solid; yield 90%; m.p. 135-136 °C. ^1H NMR (300 MHz, CDCl_3): δ 2.90 (2H, t, $J=6.3$ Hz, CH_2), 3.00-3.10 (2H, m, CH_2), 3.94 (6H, s, $2 \times \text{OCH}_3$), 3.96 (6H, s, $2 \times \text{OCH}_3$), 6.54 (1H, d, $J=15.6$ Hz, vinylic H), 6.88-6.95 (2H, m, ArH), 7.08-7.20 (4H, m, ArH), 7.32 (1H, s, vinylic H) and 7.61 (1H, d, $J=15.6$ Hz, vinylic H). ^{13}C NMR (75 MHz,

CDCl₃): δ 23.45, 26.88, 56.29 (x2), 56.38 (x2), 110.29, 111.54, 112.70, 113.43, 113.80, 118.48, 122.78, 124.32, 128.87, 129.63, 130.99, 137.32, 140.22, 149.28, 149.61, 150.23, 151.34, 170.65 and 193.87. IR, KBr Disc, ν : 3431, 2927, 1620, 1592, 1513, 1384, 1255, 1137, 1019 and 613 cm⁻¹. UV-Vis MeOH, λ_{max} : 220 and 264 nm. MS (EI) 70eV, m/z (rel. intensity): 422 (M⁺, 0.2), 362 (4), 274 (100), 259 (21) and 231 (16). HRMS calculated for C₂₅H₂₆O₆: 422.1729, found: 422.1755. APCI-MS (-ve ion mode), m/z (rel. intensity): 421 ([M-1], 100).

2-[(E)-3-(4-Nitrophenyl)acryloyl]-5-[1-(4-nitrophenyl)-meth-(E)-ylidene]-cyclopentanone (2h). Reddish brown solid; yield 84%; m.p. 204-206 °C. ¹H NMR (300 MHz, CDCl₃): δ 2.99 (2H, t, J=5.4 Hz, CH₂), 3.09-3.13 (2H, m, CH₂), 6.86 (1H, d, J=15.6 Hz, *E*-vinylic H), 7.62-7.83 (7H, m, ArH, vinylic H) and 8.28-8.35 (3H, m, ArH, vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 23.57, 26.91, 115.77, 124.41, 124.27, 129.00, 129.85, 131.52, 132.29, 138.25, 140.57, 142.05, 143.16, 147.60, 148.13, 171.44 and 192.17. IR, KBr Disc, ν : 3423, 1631, 1595, 1384, 1342, 1184, 855 and 756 cm⁻¹. UV-Vis MeOH, λ_{max} : 220 and 355 nm. MS (EI) 70eV, m/z (rel. intensity): 392 (M⁺, 0.2), 259 (100), 217 (5), 141 (1.5) and 74 (49). HRMS calculated for C₂₁H₁₆N₂O₆: 392.1008, found: 392.1012.

2-[(E)-3-(Phenylacryloyl)]-6-[1-phenylmeth-(E)-ylidene]cyclohexanone (3a). Yellow solid; yield 77% (lit.²⁰ yield 72%); m.p. 110-112 °C (lit.²⁰ m.p. 130-132 °C). ¹H NMR (300 MHz, CDCl₃): δ 1.77-1.86 (2H, m, CH₂), 2.71 (2H, t, J=6.0 Hz, CH₂), 2.77-2.81 (2H, m, CH₂), 7.15 (1H, d, J=15.6 Hz, *E*-vinylic H), 7.33-7.44 (8H, m, ArH), 7.61-7.63 (2H, m, ArH), 7.75 (1H, s, vinylic H) and 7.79 (1H, d, J=15.6 Hz, *E*-vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 23.34, 24.83, 27.48, 109.30, 120.92, 128.51, 128.71, 129.33, 130.27, 130.46, 130.57, 132.54, 133.79, 135.72, 136.76, 142.52, 179.02 and 185.88. IR, KBr Disc, ν : 3447, 2947, 1631, 1610, 1674, 1443, 1339, 1276, 974, 926, 770 and 690 cm⁻¹. UV-Vis, MeOH, λ_{max} : 237, 320 and 378 nm. MS (EI), 70eV, m/z (rel. intensity): 316 (M⁺, 5.6), 228 (100), 213 (8), 137 (1.5) and 115 (5.4). HRMS calculated for C₂₂H₂₀O₂: 316.1463, found: 316.1482.

2-[(E)-3-(4-Chlorophenyl)acryloyl]-6-[1-(4-chlorophenyl)meth-(E)-ylidene]-cyclohexanone (3b). Dark yellow solid; yield 73% (lit.²⁰ yield 68%); m.p. 173-175 °C (lit.²⁰ m.p. 173-175 °C). ¹H NMR (300 MHz, CDCl₃): δ 1.82 (2H, m, CH₂), 2.68-2.74 (4H, m, 2xCH₂), 7.10 (1H, d, J=15.3 Hz, *E*-vinylic H), 7.34 (6H, m, ArH), 7.52-7.59 (2H, m, ArH) and 7.68-7.77 (2H, m, vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 23.22, 24.75, 27.45, 109.45, 121.31, 128.98, 129.61, 129.83, 131.67, 132.55, 134.04, 134.15, 134.44, 135.13, 136.48, 141.17, 178.79 and 185.59. IR, KBr Disc, ν : 2916, 2849, 1614, 1488, 1085, 1010, 973, 816 and 718 cm⁻¹. UV-Vis MeOH, λ_{max} : 236, 316 and 384 nm. MS (EI) 70 eV, m/z (rel. intensity): 384 (M⁺, 100), 344 (4), 217 (11), 194 (14) and 138 (12). HRMS calculated for C₂₂H₁₈Cl₂O₂: 384.0684, found: 384.0681.

2-[(E)-3-*p*-Tolylacryloyl]-6-[1-*p*-tolylmeth-(E)-ylidene]cyclohexanone (3c). Orange needles; yield 71%; m.p. 180-181 °C. ¹H NMR (300 MHz, CDCl₃): δ 1.79-1.83 (2H, m, CH₂), 2.40 (6H, s, 2xCH₃), 2.69 (2H, t, J=6.0 Hz, CH₂), 2.75-2.80 (2H, m, CH₂), 7.09 (1H, d, J=15.6 Hz, *E*-vinylic H), 7.24-7.37 (4H, m, ArH), 7.35 (2H, d, J=7.8 Hz, ArH), 7.51 (2H, d, J=7.8 Hz, ArH), 7.71 (1H, s, vinylic H), 7.75 (1H, d, J=15.6 Hz, *E*-vinylic H) and 7.20 (1H, brs, chelated OH). ¹³C NMR (75 MHz, CDCl₃): δ 21.78, 21.93, 23.35, 24.82, 27.58, 109.11, 119.91, 128.70, 129.47,

130.06, 130.53, 132.88, 133.02, 133.74, 133.95, 138.67, 141.02, 142.44, 179.11 and 185.83. IR, KBr Disc, ν : 3022, 2936, 2857, 1613, 1510, 1174, 977 and 807 cm^{-1} . UV-Vis MeOH, λ_{max} : 220, 235 and 352 nm. MS (EI) 70eV, m/z (rel. intensity): 344 (M^+ , 100), 252 (3.6), 197 (3.4) and 171 (2.7). HRMS calculated for $\text{C}_{24}\text{H}_{24}\text{O}_2$: 344.1776, found: 344.1771.

2-[(E)-3-(4-Hydroxyphenyl)acryloyl]-6-[1-(4-hydroxyphenyl)meth-(E)-ylidene]-cyclohexanone (3d). Dark orange solid; yield 88%; m.p. 214-216 °C. ^1H NMR (300 MHz, DMSO-d_6): δ 1.65-1.75 (2H, m, CH_2), 2.62-2.70 (4H, m, $2\times\text{CH}_2$), 6.82-6.84 (4H, m, ArH), 7.10 (1H, d, $J=15.3$ Hz, *E*-vinylic H), 7.37 (2H, d, $J=8.4$ Hz, ArH), 7.51 (1H, s, vinylic H), 7.59-7.65 (3H, m, ArH, vinylic H), 9.92 (1H, bs, OH) and 10.06 (1H, bs, OH). ^{13}C NMR (75 MHz, CDCl_3): δ 23.41, 24.29, 27.65, 109.15, 116.34, 116.72, 117.93, 126.92, 127.54, 130.92, 131.60, 132.98, 133.77, 142.91, 158.90, 160.79, 179.34 and 185.49. IR, KBr Disc, ν : 3346, 2927, 1627, 1596, 1513, 1440, 1309, 1164 and 826 cm^{-1} . UV-Vis, MeOH, λ_{max} : 220 and 249 nm. MS (EI) 70eV, m/z (rel. intensity): 348 (M^+ , 0.9), 260 (11.2), 244 (100), 147 (17.5) and 120 (72). HRMS calculated for $\text{C}_{22}\text{H}_{20}\text{O}_4$: 348.1361, found: 348.1341.

2-[(E)-3-(4-Methoxyphenyl)acryloyl]-6-[1-(4-methoxyphenyl)meth-(E)-ylidene]-cyclohexanone (3e). Dark orange solid; yield 91% (lit.²⁰ yield 8%); m.p. 143-145 °C (lit.²⁰ m.p. 146-148 °C). ^1H NMR (300 MHz, CDCl_3): δ 1.80-1.84 (2H, m, CH_2), 2.69 (2H, t, $J=6.0$ Hz, CH_2), 2.76-2.79 (2H, m, CH_2), 3.86 (3H, s, OCH_3), 3.87 (3H, s, OCH_3), 6.93-7.04 (5H, m, ArH, *E*-vinylic H), 7.42 (2H, d, $J=8.7$ Hz, ArH), 7.57 (2H, d, $J=8.7$ Hz, ArH), 7.69 (1H, s, vinylic H) and 7.75 (1H, d, $J=15.6$ Hz, *E*-vinylic H). ^{13}C NMR (75 MHz, CDCl_3): δ 23.28, 24.79, 27.63, 55.74, 55.82, 108.85, 114.22, 114.77, 118.57, 128.54, 129.46, 130.39, 131.75, 132.20, 133.37, 142.06, 159.94, 161.73, 179.13 and 185.68. IR, KBr Disc, ν : 3432, 2947, 1630, 1597, 1384, 1253, 1169, 1025 and 829 cm^{-1} . UV-Vis, MeOH, λ_{max} : 222 and 271 nm. MS (EI) 70eV, m/z (rel. intensity): 376 (M^+ , 8.2), 258 (2.7), 178 (9), 135 (100). HRMS calculated for $\text{C}_{24}\text{H}_{24}\text{O}_4$: 376.1674, found: 376.1673.

2-[(E)-3-(4-Hydroxy-3-methoxyphenyl)acryloyl]-6-[1-(4-hydroxy-3-methoxyphenyl)meth-(E)-ylidene]cyclohexanone (3f). Dark orange solid; yield 86% (lit.²⁰ yield 75%); m.p. 175-176 °C (lit.²⁰ m.p. 176-177 °C). ^1H NMR (300 MHz, CDCl_3): δ 1.81-1.85 (2H, m, CH_2), 2.69 (2H, t, $J=6.0$ Hz, CH_2), 2.79 (2H, m, CH_2), 3.93 (3H, s, OCH_3), 3.97 (3H, s, OCH_3), 5.79 (1H, brs, OH), 5.89 (1H, brs, OH), 6.99 – 7.08 (6H, m, ArH, *E*-vinylic H), 7.20 (1H, d, $J=8.1$ Hz, ArH), 7.67 (1H, s, vinylic H) and 7.75 (1H, d, $J=15.6$ Hz, *E*-vinylic H). ^{13}C NMR (75 MHz, CDCl_3): δ 23.45, 24.33, 27.71, 56.48, 56.66, 109.24, 112.46, 115.30, 116.36, 116.50, 118.13, 124.58, 124.78, 127.40, 128.01, 131.14, 134.12, 143.33, 148.26, 148.37, 148.85, 150.40, 179.43 and 185.39. IR, KBr Disc, ν : 3423, 3248, 2930, 1598, 1550, 1507, 1432, 1384, 1273, 1209, 1159, 969 and 809 cm^{-1} . UV-Vis, MeOH, λ_{max} : 220 and 265 nm. MS (EI) 70eV, m/z (rel. intensity): 408 (M^+ , 0.25), 232 (46), 150 (100), 135 (2.3) and 107 (3). HRMS calculated for $\text{C}_{24}\text{H}_{24}\text{O}_6$: 408.1573, found: 408.1566.

2-[(E)-3-(3,4-Dimethoxyphenyl)acryloyl]-6-[1-(3,4-dimethoxyphenyl)meth-(E)-ylidene]cyclohexanone (3g). Dark orange needles; yield 92%; m.p. 146-147 °C. ^1H NMR (300 MHz, CDCl_3): δ 1.84-1.86 (2H, m, CH_2), 2.72 (2H, t, $J=5.7$ Hz, CH_2), 2.82 (2H, m, CH_2), 3.92

(3H, s, OCH₃), 3.94 (3H, s, OCH₃), 3.95 (3H, s, OCH₃), 3.96 (3H, s, OCH₃), 6.89-7.27 (7H, m, ArH, *E*-vinylic H), 7.69 (1H, s, vinylic H) and 7.75 (1H, d, J=15.3 Hz, *E*-vinylic H). ¹³C NMR (75 MHz, CDCl₃): δ 23.39, 24.80, 27.68, 56.31, 56.33, 56.37, 56.40, 108.89, 110.53, 111.27, 111.55, 113.78, 118.71, 123.16, 123.81, 128.80, 129.73, 132.00, 133.64, 142.41, 149.02, 149.62 (x2), 151.52, 179.12 and 185.50. IR, KBr Disc, ν: 3439, 2933, 2839, 1631, 1594, 1516, 1384, 1261, 1138, 1022 and 963 cm⁻¹. UV-Vis MeOH, λ_{max}: 220 and 263 nm. MS (EI) *m/z* (rel. intensity): 436 (M⁺, 29), 407 (18), 246 (100), 208 (80) and 151 (16). HRMS calculated for C₂₆H₂₈O₆: 436.1886, found: 436.1879.

Acknowledgements

Financial support from Nova Scotia Health Research Foundation (AJ, DY) and Natural Science and Engineering Research Council of Canada (AJ) is gratefully acknowledged. RGH thanks Cancer Care Nova Scotia for Norah Stephan Oncology Scholarship.

References

1. Sharma, R. A.; Gescher, A. J.; Steward, W. P. *Eur. J. Cancer* **2005**, *41*, 1955.
2. Lim, G. P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S. A.; Cole, G. M. *J. Neurosci.* **2001**, *21*, 8370.
3. De Clercq, E. *Med. Res. Rev.* **2000**, *20*, 323.
4. Mazumder, A.; Neamati, N.; Sunder, S.; Schulz, J.; Pertz, H.; Eich, E.; Pommier, Y. *J. Med. Chem.* **1997**, *40*, 3057.
5. Kopani, M.; Celec, P.; Danisovic, L.; Michalka, P.; Biro, C. *Clin. Chim. Acta* **2006**, *364*, 61.
6. Zeitlin, P. *New Engl. J. Med.* **2004**, *351*, 606.
7. National Cancer Institute, Clinical Development Plan: Curcumin. *J. Cell. Biochem.* **1996**, *26S*, 72.
8. Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. S. *Planta Med.* **1998**, *64*, 353.
9. Sharma, R. A.; McLelland, H. R.; Hill, K. A.; Ireson, C. R.; Euden, S. A.; Manson, M. M.; Pirmohamed, M.; Marnett, L. J.; Gescher, A. J.; Steward, W. P. *Clin. Cancer Res.* **2001**, *7*, 1894.
10. National Institute of Aging, A phase II, double-blind, placebo-controlled study of the safety and tolerability of two doses of curcumin C3 complex versus placebo in patients with mild to moderate Alzheimer's disease, 2006, <http://clinicaltrials.gov/show/NCT00099710>.
11. Ramsey, B. A phase I safety and dose finding study of orally administered curcuminoids in adult subjects with cystic fibrosis who are homozygous for delta F508 cystic fibrosis

- transmembrane conductance regulator (Δ F508 CFTR) mutation, **2005**, <http://www.clinicaltrials.gov/ct/show/NCT00219882>.
12. Lee, S. L.; Huang, W. J.; Lin, W. W.; Lee, S. S.; Chen, C. H. *Bioorg. Med. Chem.* **2005**, *13*, 6175.
 13. Ishida, J.; Ohtsu, H.; Tachibana, Y.; Nakanishi, Y.; Bastow, K. F. Nagai, M.; Wang, H. K.; Itokawa, H.; Lee, K. H. *Bioorg. Med. Chem.* **2002**, *10*, 3481.
 14. Youssef, K. M.; El-Sherbeny, M. A.; El-Shafie, F. S.; Farag, H. A.; Al-Deeb, O.A.; Awadalla, S. A. A. *Arch. Pharm. Pharm. Med. Chem.* **2004**, 337, 42.
 15. Ohtsu, H.; Xiao, Z.; Ishida, J.; Nagai, M.; Wang, H.K.; Itokawa, H.; Su, C.Y.; Shih, C.; Chiang, T.; Chang, E.; Lee, Y.F.; Tsai, M.Y.; Chang, C.; Lee, K.H. *J. Med. Chem.* **2002**, *45*, 5037.
 16. Jha, A.; Zhao, J.; Cameron, T. S.; DeClercq, E.; Manavathu, E. K.; Stables, J. P. *Lett. Drug Design Discov.* **2006**, *3*, 304.
 17. Ohtsu, H.; Itokawa, H.; Xiao, Z.; Su, C.Y.; Shih, C.C.Y.; Chiang, T.; Chang, E.; Lee, Y.; Chiu, S.Y.; Chang, C.; Lee, K.H. *Bioorg. Med. Chem.* **2003**, *11*, 5083.
 18. Babu, K. V. D.; Rajasekharan, K. N. *Org. Prep. Proc. Int'l.* **1994**, *26*, 674.
 19. Carruthers, W. In *Some Modern Methods of Organic Synthesis* 3rd Edition, Cambridge University Press: Cambridge (UK) 1998, p 8.
 20. Samula, K.; Kardasz, K. *Pol. J. Chem.* **1985**, *59*, 73.
 21. Gu, J.-X.; Li, Z.-Y.; Lin, G.-Q. *Tetrahedron Asymm.* **1992**, *3*, 1523.
 22. Azarifar, D.; Ghasemnejad, H. *Molecules*, **2003**, *8*, 642.
 23. Esmaeili, A. A.; Tabas, M. S.; Nasser, M. A.; Kazemi, F. *Monatsh. Chem.*, **2005**, *136*, 571.
 24. Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. *Tetrahedron* **2001**, *57*, 9225.
 25. El Ashry, E. S. H.; Kassem, A. A. *Arkivoc* **2006**, (ix), 1.